^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
KUR-502
i
Other names: KUR-502, KUR-502 CAR-NKT Therapy, CD19.CAR-aNKT cells, CD19.CAR Allogeneic NKT, CMD-502
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Athenex, Baylor College of Medicine, Texas Children’s Hospital
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
1year
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) (clinicaltrials.gov)
P1, N=48, Recruiting, Baylor College of Medicine | Trial primary completion date: Apr 2023 --> Apr 2024
Trial primary completion date
|
CD19 positive
|
cyclophosphamide • CD19 specific CAR T cell therapy • KUR-502
over1year
ANCHOR2: Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies (clinicaltrials.gov)
P1, N=36, Recruiting, Athenex, Inc. | Not yet recruiting --> Recruiting
Enrollment open
|
CD19 (CD19 Molecule)
|
cyclophosphamide • KUR-502
almost2years
ANCHOR2: Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies (clinicaltrials.gov)
P1, N=36, Not yet recruiting, Athenex, Inc.
New P1 trial
|
CD19 (CD19 Molecule)
|
cyclophosphamide • KUR-502
over3years
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) (clinicaltrials.gov)
P1, N=48, Recruiting, Baylor College of Medicine | N=20 --> 48
Clinical • Enrollment change
|
CD19 (CD19 Molecule)
|
CD19 positive
|
fludarabine IV • CD19 specific CAR T cell therapy • KUR-502 • cyclophosphamide intravenous
Share via
